Telix Pharmaceuticals (ASX:TLX) - Aandelenkoers, Nieuws & Analyse

TLX Overzicht aandelen

TLX fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	6/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 48% onder onze schatting van de reële waarde

De winst zal naar verwachting met 38.32% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Telix Pharmaceuticals Limited Concurrenten

Race Oncology

ASX:RAC

AU$237.8m

Clinuvel Pharmaceuticals

ASX:CUV

AU$680.3m

CSL

ASX:CSL

AU$131.4b

Orthocell

ASX:OCC

AU$151.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Telix Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	AU$22.96
52 Week Hoogtepunt	AU$23.99
52 Week Laag	AU$9.06
Bèta	2.38
11 maand verandering	6.84%
3 maanden verandering	16.08%
1 Jaar Verandering	151.20%
33 jaar verandering	214.95%
5 jaar verandering	1,219.54%
Verandering sinds IPO	2,881.82%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	TLX	AU Biotechs	AU Markt
7D	-0.09%	-5.0%	1.4%
1Y	151.2%	9.8%	17.7%

Rendement versus industrie: TLX overtrof de Australian Biotechs industrie, die het afgelopen jaar een rendement 9.8 % opleverde.

Rendement versus markt: TLX overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.7 %.

Prijsvolatiliteit

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement	5.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: TLX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van TLX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	423	Chris Behrenbruch	telixpharma.com

Telix Pharmaceuticals Limited, een biofarmaceutisch bedrijf in commerciële fase, richt zich op de ontwikkeling en commercialisering van therapeutische en diagnostische radiofarmaceutica voor kanker en zeldzame ziekten in Australië, België, Japan, Zwitserland en de Verenigde Staten. Het bedrijf biedt Illuccix aan voor de behandeling van prostaatkanker en TLX66-CDx voor de behandeling van osteomyelitis. Tot de kandidaat-producten behoren TLX591, een radiografisch antilichaam-drug-conjugaat voor de behandeling van prostaatkanker; TLX250-CDx voor de behandeling en diagnose van nierkanker; TLX101-CDx voor hersenkanker (glioom); TLX66-CDx voor de behandeling van beenmergconditionering; TLX300-CDx voor de behandeling en diagnose van weke delen sarcoom; en TLX250 voor de behandeling van heldercellig niercelcarcinoom.

Telix Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Telix Pharmaceuticals zich tot de beurswaarde?
TLX fundamentele statistieken
Marktkapitalisatie	AU$7.70b
Inkomsten(TTM)	AU$49.19m
Inkomsten(TTM)	AU$645.68m

156.2x

Koers/Winstverhouding

11.9x

P/S-verhouding

Is TLX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TLX resultatenrekening (TTM)
Inkomsten	AU$645.68m
Kosten van inkomsten	AU$240.33m
Brutowinst	AU$405.35m
Overige uitgaven	AU$356.16m
Inkomsten	AU$49.19m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.15
Brutomarge	62.78%
Nettowinstmarge	7.62%
Schuld/Eigen Vermogen Verhouding	2.9%

Hoe presteerde TLX op de lange termijn?

Bekijk historische prestaties en vergelijking

TLX Overzicht aandelen

Beloningen

Risicoanalyse

Telix Pharmaceuticals Limited Concurrenten

ASX:RAC

AU$237.8m

ASX:CUV

AU$680.3m

ASX:CSL

AU$131.4b

ASX:OCC

AU$151.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Consensus EPS estimates fall by 23%

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings: EPS misses analyst expectations

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Price target increased by 12% to AU$24.04

Price target increased by 10% to AU$20.87

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Price target increased by 14% to AU$21.49

Consensus EPS estimates increase by 10%

Price target increased by 11% to AU$18.89

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Consensus EPS estimates increase by 10%

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Consensus EPS estimates increase by 30%

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Consensus EPS estimates fall by 19%

Price target increased by 7.5% to AU$14.47

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Price target increased by 8.0% to AU$13.37

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022)

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Price target increased by 7.5% to AU$11.82